Clinical Trials Logo
  1. Home
  2. Leukemia, Lymphocytic, Acute
  3. NCT00483132
  4. Details
NCT00483132 Clinical Trial

Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III

Leukemia, Lymphocytic, Acute Clinical Trial

Official title:
Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00483132
Other study ID # GOELAL02
Secondary ID
Status Completed
Phase Phase 3
First received June 5, 2007
Last updated June 5, 2007
Start date September 1994
Est. completion date April 2002

Study information
Verified date June 2007
Source French Innovative Leukemia Organisation
Contact n/a
Is FDA regulated No
Health authority France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Study type Interventional

Clinical Trial Summary

Improved outcome of high risk lymphoblastic leukemia (ALL) with laite high dose therapy.

High dose versus conventional therapy for adult low risk T-ALL and Lymphoblastic lymphoma (LBL).

Description:

Comparison between two autograf therapeutic strategies in high risk patients Ramdomised comparison between maintenance treatment with or not interferon alpha 2 a

Recruitment information / eligibility
Status Completed
Enrollment 232
Est. completion date April 2002
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 15 Years to 65 Years
Eligibility Inclusion Criteria

- ALL high risk or low risk or lymphoblastic lymphoma

- age 15-55 years old

- informed consent signed

Exclusion Criteria:

- patients previously treated with a chemotherapy or alpha-interferon

- ALL 3 (burkitt like)

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• interferon alpha 2a

Locations
Country Name City State
France INorbert IFRAH Angers chu ANGERS

Sponsors (1)
Lead Sponsor Collaborator
Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang GOELAMS

Country where clinical trial is conducted

France, 

References & Publications (1)

Hunault M, Harousseau JL, Delain M, Truchan-Graczyk M, Cahn JY, Witz F, Lamy T, Pignon B, Jouet JP, Garidi R, Caillot D, Berthou C, Guyotat D, Sadoun A, Sotto JJ, Lioure B, Casassus P, Solal-Celigny P, Stalnikiewicz L, Audhuy B, Blanchet O, Baranger L, Bé — View Citation

Outcome
Type Measure Description Time frame Safety issue
Primary overall survival time to death
Secondary Efficacy of study treatments time to end of treatment
See also
  Status Clinical Trial Phase
Terminated NCT00393380 - Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor Phase 2
Terminated NCT00313053 - Study of mAb 216 With Chemotherapy for Treatment of Pediatric Relapsed or Refractory B-progenitor Acute Lymphoblastic Leukemia Phase 1
Recruiting NCT04940468 - High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology N/A
Terminated NCT00176930 - Stem Cell Transplant for Hematological Malignancy N/A
Completed NCT00406393 - Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) Phase 3
Completed NCT01078337 - T-cell Minimal Residual Disease (MRD) Evaluation Using Flow Cytometric Analysis N/A
Completed NCT00246662 - Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies Phase 1
Terminated NCT01100658 - Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors N/A
Terminated NCT00185523 - Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML) Phase 2
Completed NCT00905034 - Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage Phase 2
Recruiting NCT00526084 - Functional Pharmacogenomics of Childhood Acute Lymphoblastic Leukemia in Taiwan N/A
Completed NCT00005892 - Study of Allogeneic Bone Marrow Transplantation Following Cyclophosphamide and Radiotherapy in Patients With Myelodysplastic Syndrome and Acute Leukemia Related to Fanconi's Anemia N/A
Recruiting NCT03544021 - CART-19 FOR Relapsed/Refractory Acute Lymphoblastic Leukemia （ALL） Phase 1/Phase 2
Terminated NCT00176839 - Stem Cell Transplantation for Hematological Malignancies Phase 2/Phase 3
Not yet recruiting NCT05565105 - CD34+ Transplants for Leukemia and Lymphoma Phase 2
Not yet recruiting NCT05154474 - Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy
Terminated NCT00907517 - Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247) Phase 1
Terminated NCT01050946 - Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit Phase 2
Completed NCT00537550 - Adult ALL Treatment at Diagnosis N/A
Terminated NCT00167180 - Post Transplant Donor Lymphocyte Infusion Phase 2